Alexion plans to initiate a phase II/III study in children and adolescents with neuromyelitis optica spectrum disorder (NMOSD) in mid-2020.Amgen AMGN will also begin clinical studies to evaluate inflammatory drug, Otezla, to treat respiratory distress in late-stage COVID-19 patients.